PressSeptember 2, 2022 Core One Rolls Out Commercial Sales Strategy for its Revolutionary API Grade Biosynthetic Psilocybin
PressSeptember 1, 2022 Lobe Sciences and Cantheon Capital Enter into Exclusive Investment Agreement to Fund $1.5M USD Toward Clinical Trials in Australia
PressSeptember 1, 2022 PanGenomic Health Inc Signs a Non-binding Letter of Intent for the Acquisition of Mindleap Health Inc.
PressSeptember 1, 2022 Filament Health and ATMA Journey Centers Announce 14 Subjects Dosed in Health Canada-Approved Psilocybin Clinical Trial
PressAugust 31, 2022 Bright Minds Biosciences Initiates Dosing in Phase I Clinical Trial of BMB-101 for Dravet Syndrome
PressAugust 31, 2022 PSYC Completes and Publishes 2021 Audited Financials; Will Begin Audit of Q1 & Q2 2022
PressAugust 31, 2022 Mindset Pharma Further Expands its IP Portfolio with Three Additional Non-Tryptamine Families of Next-Generation Psychedelic Compounds
BlogAugust 31, 2022 Amanda Reiman Plants Seeds for the Growth of Plant Medicines – Podcast Episode #15
PressAugust 30, 2022 Optimi Health Enters Into International Collaborative Research and Supply Agreement With Promises Innovative Recovery Center
PressAugust 30, 2022 Field Trip Health & Wellness Ltd. Reports Fiscal First Quarter 2023 Financial and Operating Results
PressAugust 30, 2022 Braxia Scientific Reports Q1 2023 Financial Results; Launches KetaMD in U.S. Increasing Treatment Access for Mental Health Patients
